[First experience in clinical trials of the new domestic drug acediprol used in the treatment of cardiac arrhythmias].
The antiarrhythmic effect of sodium valproate (acidoprol) on the degree of arrhythmic manifestations was examined in 18 patients with neurocirculatory dystonia (NCD) and 19 with coronary heart disease (CHD). A 24-hour ECG monitoring and recording were performed on emotional stress and exercise. The antiarrhythmic effect of the agent was evaluated by the blind method and placebo. The course of its therapy was found to reduce the frequency of ventricular premature contractions in 14 patients with NCD and to substantially limit or eliminate the arrhythmogenic effect of emotional stress and exercise. In CHD, the antiarrhythmic effect of acedoprol was less, it being shown only by 6 patients, but the effect failed to occur during exercise. However, the arrhythmogenic effect of emotional stress in CHD was significantly limited. Thus, the GAMA-ergic, stress-limiting system activator acedoprol has antiarrhythmic activity in cardiac patients, but its activity is drastically pronounced in NCD and less marked in CHD.
Meerson
F Z
FZ
Skibitskiĭ
V V
VV
Petrova
T R
TR
D000328:Adult; D000704:Analysis of Variance; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D003327:Coronary Disease / Q000150:complications; D004311:Double-Blind Method; D015716:Electrocardiography, Ambulatory; D005080:Exercise Test; D006801:Humans; D008875:Middle Aged; D009449:Neurocirculatory Asthenia / Q000150:complications; D014635:Valproic Acid / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D014635:Valproic Acid
Pervyĭ opyt klinicheskogo issledovaniia novogo otechestvennogo preparata atsediprola v lechenii narusheniĭ ritma serdtsa.